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Abstract 
 Cervical cancer is the second most common cancer among women worldwide 
with half a million of new cases every year. Cervical cancer is caused by oncogenic 
human papillomaviruses (HPVs), with HPV16 and 18 being the most frequently 
detected types. Genital HPV infections are common in the general population 
although most infections are cleared before causing malignancy. However a small 
proportion of the infections evade the immune system, become persistent and may 
cause cervical lesions and even invasive disease. Being the causative agent for 
cervical malignancy, HPV is an obvious target for cervical cancer diagnosis and 
prevention. Current screening programs, primarily based on cervical cytology, 
produce millions of suspicious samples every year. Specific tools to identify high-
grade disease in these samples are needed to increase specificity for malignancy and 
thereby reduce referral rates and overtreatment. 
 In the current study, monoclonal antibodies were raised against the HPV E7 
oncoprotein. E7 is an absolute prerequisite for malignant transformation and the 
protein is expressed at increasing levels during cancer development. E7 is therefore a 
suitable marker for HPV-induced malignancy. Antibodies specific for the E7 protein 
of oncogenic HPV types were selected using immunological methods such as 
ELISA, Western blot, Immunocytochemistry and flow cytometry. Phage display was 
used to identify antibody epitopes thereby predicting and verifying antibody 
specificity. Two of the antibodies, recognizing HPV16 and 18 E7 respectively, 
demonstrated strong staining of dysplastic cells in HPV-positive specimens in 
immunocytochemistry and may thus have the potential to be used in a clinical 
setting. Since the antibodies detect the protein in Liquid-based cytology, which 
normally leaves residual sample after standard cytology, E7 testing can easily be 
performed without recalling the patient for additional sampling. 
 Immunological detection of the E7 oncoprotein is an attractive alternative for 
triage of suspicious and borderline cytology to highlight and identify the often rare 
dysplastic cells present in a cell scrape. E7 detection can further reduce subjectivity 
and be performed with only standard equipment and thereby make HPV-testing 
available also in less developed regions. 
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Introduction 
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Cervical cancer is the second most common cancer in women worldwide, 
with half a million new cases every year. Cervical cancer is caused by a 
limited number of oncogenic human papillomaviruses (HPVs) and viral DNA 
can be detected in almost all cancers (99.7 %)1. Most women and men are 
infected with genital HPV at least once in their life-time and the prevalence 
of genital HPV is over 10 % in the world2. The vast majority of all infections 
are transient and/or asymptomatic. However, a small proportion will evade 
the immune system and if left untreated, progress to cancer. The major 
challenge in cervical cancer diagnosis and management is thus to 
discriminate persistent high-risk infections, that should be treated or closely 
monitored, from transient infections and low-grade lesions that will regress, 
while minimizing overtreatment and unnecessary recalling of patients. 
The Pap test is the most widely used screening method, often complemented 
by colposcopy and histology. In the Pap test, the morphology of exfoliated 
cervical cells is studied to identify pre-malignant and cancerous cells. Pap 
screening has reduced the number of cancer cases dramatically in many 
areas3, 4, but to be efficient the test has to be repeated frequently and requires 
trained personnel. Millions of pap tests yield inconclusive or borderline 
results every year and require further sampling and evaluation to identify 
underlying disease. In addition, many women in the world are not included in 
a cervical cancer prevention program and thus cervical cancer still causes 
270 000 deaths every year5. 
To reduce the number of cancer cases, both in regions with and without 
functional screening, more cost-effective, cancer-specific and preferably 
objective diagnostic methods are needed. Since Harald zur Hausen’s 
discovery of the causality between high-risk HPV infection and cervical 
cancer in 1980, for which he was awarded with the Nobel Prize in physiology 
or medicine in 2008, a lot of effort has been put into understanding the viral 
life cycle and its ability to induce malignancy. Based on this knowledge HPV 
has become an important target for diagnosis and prevention of cervical 
cancer. 
This thesis describes the generation of monoclonal antibodies (mAbs) 
detecting the E7 oncoprotein of carcinogenic HPV types and the 
characterization of the antibodies with special reference to their ability to 
specifically recognize E7 of high-risk types and finally a preliminary 
evaluation of their usefulness for immunological detection of E7 oncoprotein 
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in clinical specimens. Different immunization and selection strategies were 
used to obtain antibodies with desired functionalities. Antibodies were 
identified that proved to be useful in different immunological methods for E7 
detection and can hopefully be used for development of more specific tests 
for early diagnosis of HPV-induced malignancy. 
 
 
Papillomaviruses are small, non-enveloped DNA viruses infecting epithelial 
surfaces in most vertebrates. The viruses cause a broad range of disease in 
humans, such as anogenital cancer, head- and neck cancer, skin or genital 
warts and recurrent respiratory papillomatosis. The outcome of the infection 
will depend on HPV type and site of infection as well as different host 
factors. HPV is necessary for the development of cervical cancer and viral 
DNA can be found in virtually all cases1. The two most common types in 
cervical cancer are HPV16 and 18, together responsible for approximately 
70 % of all cases6. 
So far, at least 120 HPV types with completely characterized genomes have 
been identified. The virus is classified based on the nucleotide sequence of 
the HPV L1 capsid gene and viruses with at least 10 % difference in L1 
sequence are defined as different types7. The HPV genome evolves slowly, in 
parallel with its host and has more and less conserved regions such as L1 
being well conserved and the noncoding Long control region (LCR) being 
more diverse8. 
Different HPV types target different epithelia and at least 40 types infect the 
human genital tract. Of these, 12 are frequently found in cervical cancers and 
therefore considered high-risk types9. Women, and men, are often infected 
with several HPV types at the same time, often transmitted together and 
different infections can cause independent lesions side by side in the  
cervix10, 11. HPV16 is by far the most dominant HPV type, responsible for 
55 % of the cervical cancers in the world, followed by HPV18 present in at 
least 15 % of the invasive cancers6. The other high-risk types are HPV33, 45, 
31, 58, 52, 35, 59, 51, 56 and 39 in descending order in the world-wide 
distribution though there are geographical variations6, 12. The other mucosal 
types, besides the 12 high-risk types, are classified as intermediate or low-
risk and only rarely detected in cervical cancer. HPV6 and 11 are the two 
most common genital low-risk types together responsible for 90 % of genital 
warts13. 
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The viruses are prone to cause cancer at transformation zones where two 
types of epithelia meet, especially the cervix where squamous epithelium 
replaces glandular13. Most cervical cancers are of squamous origin but 
approximately 15 % are adenocarcinomas. HPV18 is more common in 
adenocarcinoma than in Squamous cell carcinoma (SCC), detectable in 37 % 
of cases, compared to 13 % of the SCC6. Conversely, HPV16 is less 
frequently found in adenocarcinoma than in SCC. HPV16, 18 and 45 are 
often considered more aggressive since they are present in a larger proportion 
of SCC than in high-grade lesions compared to other HPV types6 (Fig. 1). 
Invasive cancer caused by HPV16, 18 and 45 is in addition diagnosed at a 
younger mean age12. 
Figure 1. Type-specific HPV prevalence in relation to cervical diagnoses. HPV16, 18 
and 45 are often considered more aggressive than the other high-risk types as the 
prevalence of these types increase more with the severity of the disease.HPV16, 18 
and 45 are further responsible for a larger portion of the adenocarcinomas (ADC) 
than squamous cell carcinoma (SCC). Multiple infections are counted several times. 
HSIL: high-grade squamous intraepithelial lesions (corresponding to Cervical 
intraepithelial neoplasia 2/3). Reprinted from14 Copyright (2008), with permission 
from Elsevier.  
 
The 8 kb circular HPV DNA genome normally encodes two classes of genes, 
Early (E) genes, E1, E2, E4, E5, E6 and E7, involved in viral replication and 
cellular transformation and Late (L) genes encoding the L1 and L2 capsid 
proteins (Fig. 2). To be able to infect, the viral particles have to reach the 
proliferating basal cells and probably do so through microabrasions in the 
epithelia, though the exact mechanisms of viral uptake is not fully 
understood15. The life cycle of the virus is then totally dependent on the 
differentiation program of the keratinocytes and cellular DNA synthesis. 
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During a productive infection, the expression of viral proteins is tightly 
regulated in order to produce infectious viral particles and avoid the immune 
system. The early proteins are expressed soon after infection but at low levels 
and the viral genome is maintained as stable episomes or plasmids, 
replicating with the cellular DNA in the basal cells15. In this initial part of the 
viral life cycle the HPV E1 and E2 proteins are necessary for replication of 
the viral DNA15. The infected basal cells undergo asymmetric mitosis, 
leaving one daughter cell as an undifferentiated proliferating basal cell acting 
as a reservoir of infection while the other becomes a differentiating 
suprabasal cell. The E6 and E7 proteins associate with cell cycle regulators 
and drive the cells, which would otherwise exit the cell cycle as they 
differentiate, into S-phase16 and are thus considered oncoproteins. As the 
infected cells spread throughout the epithelia, the expression of the E6 and E7 
oncoproteins is upregulated and the viral DNA increases in copy number. 
The capsid proteins are only expressed in the upper epithelial layers, after 
viral genome amplification15 and assemble into viral particles comprised of 
the viral genome, covered by a capsid consisting of 360 copies of the L1 
protein and 12 copies of the L2 protein. Papillomaviruses are non-lytic and 
shed when the infected cells reach the epithelial surface
17
. This infectious 
cycle takes approximately three weeks, the same time as it takes for the basal 
cells to differentiate and move up the epithelium. 
Figure 2. A schematic presentation of the HPV 16 circular DNA genome.  
The Early (E) and Late (L) genes and the Long control region (LCR) are shown. 
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The majority of the HPV infections are subclinical or cause only mild 
dysplasia, cleared by the immune system within two years although the 
mechanisms of HPV clearance are not fully understood. The immune 
response after HPV infection is normally low and/or delayed, most probably 
because of the low-level expression of the early HPV proteins, production of 
the capsid proteins only in the upper epithelial layers far from immune cells 
in the submucosa and the fact that the infection is non-lytic, thereby not 
inducing an inflammatory immune response15. 
 
If a high-risk HPV infection is not cleared by the immune system, it becomes 
persistent and able to induce malignant transformation. Cervical cancer 
development normally follows defined stages starting with infection with a 
carcinogenic HPV type followed by the establishment of viral persistence, the 
development of pre-cancer and culminating in invasion (Fig. 3). Lesions at all 
stages until invasive cancer can regress, but the chance of clearance decreases 
with the severity of the lesion. 
Figure 3. From HPV infection to cancer. The majority of the genital HPV 
infections is asymptomatic and cleared before causing visible lesions.  
The majority of all mild dysplasia regress spontaneously within less than a year.  
A proportion of the high-risk HPV infections will however become persistent and 
may, if left untreated, proceed to high-grade lesions and invasive cancer. 
The estimated life-time risk of acquiring a genital HPV infection is over 
50 %18 and most women are infected soon after becoming sexually active. 
The HPV prevalence therefore peaks in young women and is as high as 40 % 
in some female populations19. Due to the long pre-cancerous phase and the 
fact that most infections do not cause malignancy, cancer incidence in young 
women is however normally low19. Since the virus is transmitted by skin-to-
skin contact, the risk factors for acquiring HPV are linked to sexual behavior, 
such as the number of partners and other genital infections20. Approximately 
half of the carcinogenic HPV infections are resolved within six months of 
exposure and less than 10 % become persistent and are still detectable after 
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two years19. The two most important risk factors for cervical cancer are thus 
persistent infections with oncogenic HPV and lack of screening13. 
Consequently most cases and deaths from cervical cancer are in low-resource 
regions, where the possibilities to screen and treat are limited. Other minor 
risk factors for cervical cancer in HPV-infected women are multiparity21, 
inflammation22 and long-term use of oral contraceptives23. Smoking is a risk 
factor for SCC but not adenocarcinoma24. 
Viral persistence is necessary for carcinogenesis and as the probability of 
clearance decreases with time from exposure, the risk of invasion increases25 
(Fig. 4). For malignant progression however, other genetic events, induced by 
the virus, must take place in the host genome15. As discussed below, the viral 
oncoproteins interact with different cell cycle regulators, increase cell 
proliferation and induce genomic instability which leads to an accumulation 
of somatic mutations during the long pre-cancerous phase. The pre-cancer 
(Cervical intraepithelial neoplasia, CIN2/3) incidence actually peaks 
approximately 5-15 years after infection and the invasive cancer decades 
later. Approximately 1 % of all high-risk infections will finally, if left 
untreated, cause cervical cancer26. 
Figure 4. Risk of HPV persistence and cervical cancer progression. The majority of 
the HPV infections are solved within two years after infection. However, the longer 
the infection persists, the larger risk of developing high-grade dysplasia. Most high-
grade lesions (Cervical intraepithelial neoplasia, CIN3) develop many years after 
primary infection. Half of the high-grade lesions will, if left untreated proceed to 
invasive cancer and true CIN3 should be the preferred threshold for treatment. 
Reprinted from19 Copyright (2010), with permission from Wolters Kluwer Health. 
Cervical cancer precursors are often histologically classified as Cervical 
Intraepithelial Neoplasia (CIN) grade 1-3, where CIN1 is mild, CIN2 
moderate and CIN3 severe dysplasia27, defined as the extension of abnormal, 
undifferentiated cells in the epithelium caused by persistent HPV infections 
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(Fig. 5). Low-grade lesions (CIN1) are the first manifestation of the HPV 
infections, caused by both high- and low-risk HPV types. CIN1 should not be 
considered as pre-cancer and has a relatively low risk of progression to 
invasive disease. The abnormal cells only occupy the deepest third of the 
epithelium and these mild to subclinical changes are hard to detect 
histologically. CIN2 is a heterogeneous state, often with a mix of acute 
infection and severe dysplasia, with abnormal cells in two thirds of the 
epithelium. In CIN3, or carcinoma in situ, the undifferentiated cells are 
spread throughout the epithelia and this is the immediate precursor of 
invasive cancer and should always be treated due to the high risk of 
progression. 
A key event during carcinogenesis is integration of the viral DNA into the 
host genome. This is seen in most cancers as well as in many high-grade 
lesions and some low-grade lesions28. Integration is probably not necessary 
for malignancy since not all cancers have integrated viral genome, but leads 
to a more aggressive progression. Integration often leads to disruption of the 
E2 gene, which otherwise is a regulator of the E6/E7 expression. This loss of 
negative feedback control of the expression of the oncogenes results in 
elevated oncoprotein levels15. Integration cannot be considered a natural 
event in the viral life cycle since no viral particles are produced from this 
truncated integrated form. 
Figure 5.  The expression pattern of the viral proteins changes during the 
progression to cervical cancer. In the productive infection, viral particles are 
produced in the upper epithelial layers and shed. The early viral proteins are 
expressed, at moderate levels, in the lower epithelium. In high-grade dysplasia and 
cancer, there is no or very low expression of the capsid proteins, while the expression 
of the oncoproteins is upregulated, especially after viral integration. CIN: Cervical 
intraepithelial lesion; CaCx: Cervical cancer. Reproduced with permission from 
John Doorbar (2006) Clinical Science (110) p 533 © the Biochemical Society. 
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Several studies have shown that two viral proteins, E6 and E7, are necessary 
both for the induction of the malignant transformation and for maintaining 
the transformed phenotype29, 30. The E6 and E7 oncoproteins are expressed at 
increasing levels during cervical carcinogenesis31, 32 and are accepted markers 
for cervical cancer progression. E6 and E7 have numerous cellular targets, 
with the tumour suppressor p53 and the retinoblastoma protein family (pRb) 
being the most studied. By interacting with important cell cycle regulators, 
the virus overrides cell cycle check points and induces cell proliferation. The 
viral oncoproteins further inhibit apoptosis, induce genomic instability and 
increase the telomerase expression, important steps in the transformation 
towards cancer phenotype (reviewed by16) (Fig. 6).  
Figure 6. Illustration of key steps in HPV induced malignancy. In the normal cell, 
cell cycle progression is controlled by the retinoblastoma protein (pRb) and the E2F 
transcription factor. The E7 protein can, by degrading the tumour suppressor pRb, 
release E2F and induce S-phase entry in HPV-infected epithelial cells. Due to loss of 
feed-back, the levels of tumour suppressor p53 increase causing growth inhibition 
and apoptosis. When E6 is present however, p53 is degraded which leads to extended 
proliferation, loss of p53-mediated DNA damage control and accumulation of 
mutations. E6 can further activate the catalytic subunit of telomerase (hTERT) which 
is normally inactive in parabasal cells, causing telomere extension and 
immortalization16. 
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E6 and E7 of high- and low-risk HPVs have large sequence similarities and 
share some interaction partners (e.g. pRb). However, the low-risk HPV 
proteins has lower affinity to the cellular proteins and the low- (and 
intermediate) risk HPV types are not able to induce malignant 
transformation33, 34 and are seldom detected in cervical cancer. 
The E7 proteins are small acidic proteins, of approximately 100 amino acids 
(aa), with more and less conserved regions (Fig. 7). The N-terminal part of 
the protein is unfolded and flexible35. This region contains two conserved 
regions, CR1 and CR2. The conserved Leu-X-Cys-X-Glu (LXCXE) motive 
in CR2 is necessary for pRb-binding and the CR2 domain shares sequence 
similarity and transforming activity with proteins of other DNA tumour 
viruses as well (e.g. Adenovirus E1A, simian virus 40 large tumour 
antigen)36. The C-terminal end contains a third conserved region, CR3, with 
two Cys-X-X-Cys (CXXC) motifs separated by 29 or 30 residues, necessary 
for the formation of a zinc binding fold and involved in protein stabilization 
and dimerization although dimerization has not yet been shown in vivo35. 
Figure 7. Alignment of HPV16, 18, 6 and 11 E7 amino acid sequences.  
The conserved regions (CR) one to three are indicated with respect to the HPV16 E7 
amino acid sequence37. 
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The long pre-invasive phase, together with the fact the cervix is easily 
accessible for sampling and treatment, makes cervical cancer ideal for 
screening. Large parts of the world are covered by screening programs and 
this has led to a dramatic reduction in cervical cancer incidence with over 
70 % reduction in some populations4 and women diagnosed by screening 
have a significantly higher chance of being cured than those diagnosed by 
detectable symptoms38. However, many women are not yet covered by such 
programs and due to limitations of the available tests, a not insignificant 
portion of the screened women still gets cancer. 
Screening prevention programs normally include primary screening, triage of 
equivocal results and colposcopy-guided biopsy in patients identified with 
abnormal screening results, followed by treatment and follow-up. Detection 
methods, start-points and screening intervals, as well as when and how to 
treat vary between settings. For primary screening, most programs use 
cervical cytology. In the widely used Pap test (Pap smear), first described by 
George Papanicolau in the 1940s, the morphology of the exfoliated cervical 
cells is examined under magnification39. The sensitivity of the test is limited 
(around 50 % for CIN2/3) and the test needs to be repeated frequently, 
typically every 2-3 years, to be efficient26. The evaluation identifies a 
spectrum of abnormalities and is subjective. Studies have shown that even 
experienced cytologists differ in their evaluation40. 
A refinement of the Pap smear, where the cervical cells are spread directly 
onto a microscope slide, is Liquid-based Cytology (LBC). In LBC the 
exfoliated cells are first transferred into a fixative liquid and then used to 
prepare monolayer slides. LBC has been shown to increase neither sensitivity 
nor specificity compared to the conventional pap smear41, however this 
technique has two major advantages; it creates more homogenously spread 
cell preparations and it leaves residual material for further analysis such as 
HPV testing, without requiring an extra sample. Furthermore, LBC samples 
can be processed using automated systems. 
 
Two HPV vaccines are approved today, Cervarix (GlaxoSmithKline) and 
Gardasil (Merck). Both vaccines protect against HPV16 and 18 and Gardasil 
also targets HPV6 and 11 that cause genital warts. The vaccines are HPV L1 
Virus-like-particle (VLP) vaccines. The vaccines have shown almost 100 % 
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protection against the targeted HPV types and offer cross-protection against 
closely related high-risk HPV types as well42. Vaccines for protection against 
additional carcinogenic types are under evaluation. 
Since most women are infected at first intercourse, women should optimally 
be vaccinated before sexual debut. The vaccines have no therapeutic effect 
and vaccination of older, already exposed women is not protective42. For 
these generations of unvaccinated women screening will still be necessary. It 
is also important that vaccinated women continue to undergo regular cervical 
screening since the vaccines do not cover all high-risk types. There will also 
always be women who are not, for different reasons, covered by the 
vaccination program and need regular examinations. 
 
Histological evaluation has long been the gold standard for diagnosis of 
cervical malignancy and is used to verify abnormal cytology results and solve 
inconclusive cytology. In most screening programs, the threshold for 
treatment is histological CIN2 or worse, despite the fact that 40 % of the 
CIN2 lesions regress spontaneously within two years
43
. Most guidelines 
recommend treatment of the entire transformation zone at confirmed high-
grade dysplasia since the entire zone is at risk. Fertility sparing methods, such 
as cryotherapy, cone-shaped excision and loop electrosurgical excision 
procedure (LEEP) are to be preferred, but in case of cancer, surgery and even 
radical hysterectomy, in combination with radiotherapy and chemotherapy, 
might be the best choice13. Most protocols recommend treating CIN2, rather 
than waiting and observing, due to the risk of missing underlying cancers44, 45. 
This leads to a lot of overtreatment of lesions that would otherwise regress 
and which is extra problematic in women in childbearing age, due to the 
increased risk of preterm delivery following treatment46. 
The highest grade of CIN identified in a biopsy sample decides the 
management of the patient and since one patent can have several lesions of 
different severity and caused by different HPV types, the site of sampling 
becomes crucial10, 47. This, in combination with large inter-observer varia-
tions in the histological evaluation
40
, contributes to the complexity of 
diagnosing cervical pre-cancer histologically. Multiple biopsies and 
immunohistochemical staining have been suggested to increase sensitivity 
and specificity for malignancy19. 
A particular challenge in cervical cancer prevention is the management of 
low-grade and mildly atypical cervical abnormalities. The most common 
abnormality in cytology is Atypical Squamous Cells of Undetermined 
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Significance (ASC-US)48. Millions of women are actually diagnosed with 
minor or equivocal abnormalities every year49 and though most of these 
lesions will regress approximately 5% have underlying high-grade disease 
(CIN3+) that needs to be identified and treated50. The high proportion of 
inconclusive cytology results, poor reproducibility in grading of lesions and 
large number of recalled and over-treated women highlights the need for 
alternative, preferably more objective approaches, such as biomarkers to 
solve some of the problems with today’s screening methods. 
 
To increase the interobserver reproducibility, reduce subjectivity and/or 
increase specificity/sensitivity several biomarkers have been suggested in the 
diagnosis of cervical malignancy. Safer diagnosis has the potential of 
reducing the overtreatment of lesions that would otherwise regress, decrease 
the number of missed cases and hopefully make screening available for a 
larger part of the world.  
HPV DNA testing is now widely used for triage of equivocal cytology 
findings and as co-testing to cytology, but has also been for suggested as a 
more sensitive test for high-grade dysplasia compared to cytology in primary 
screening51. The primary benefits of HPV DNA testing are the high 
sensitivity and the high negative predictive value and consequently, the 
screening interval after a negative HPV DNA test can safely be lengthened to 
six years due to the low risk of high-grade dysplasia52. However, a single 
DNA tests cannot discriminate transient infections from persistent and due to 
the high prevalence of transient HPV infections in the population, especially 
in young women, the utility of HPV testing in primary screening is somewhat 
limited. Another approach claimed to be more specific for malignancy than 
DNA testing is to measure HPV mRNA. mRNA testing is generally more 
specific and less sensitive than DNA at detecting high-grade dysplasia, 
depending the detection method used53. 
Women with ASC-US and borderline cytology should always be further 
managed in order to identify those women at risk due to the risk of under-
lying high-grade disease (10-15 %)
54, 55
. High-risk HPV DNA and mRNA 
tests normally perform better in ASC-US populations than borderline49, 56. 
Since most low-grade lesions are HPV positive HPV testing is not selective 
for high-grade dysplasia in this group and especially not in women under 
5048. Thus, most guidelines recommend HPV DNA testing (in case of LBC), 
repetition of the smear and/or colposcopy for triage of ASC-US, while today 
only cytology and colposcopy is recommended for triage of borderline 
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samples57. Other complementary tests are therefore needed for the large 
group of borderline diagnoses in cytology. 
Some cellular markers have been suggested for more specific detection of 
cervical neoplasia. So far, the tumour suppressor gene p16 (p16ink4a) is the 
most widely evaluated and promising cellular marker. p16 is overexpressed 
in high-grade dysplasia and cervical cancer due to E7-induced pRb 
degradation and loss of negative feedback58. p16 cytology has been shown to 
have higher specificity but lower sensitivity for CIN2+ than HPV DNA 
testing59. To further improve the test performance and facilitate the 
interpretation of the staining results, the combination of p16 and the 
proliferation marker Ki-67 has been introduced (mtm laboratories)60. This 
dual staining protocol, judging a sample as positive based on the detection of 
at least one double stained cell irrespective of cellular morphology, has been 
shown to be more specific for detection of CIN2+ in the ASC-US and low-
grade lesions compared to both HPV DNA testing and p16 single-stain 
cytology61. 
Although the importance of the viral proteins for the malignant 
transformation is well established, no HPV protein test has yet been FDA 
approved, which is probably due to the lack of sensitive reagents. A few 
groups have managed to detect viral protein markers in clinical material e.g. 
E731, 62, E663 and L164, but larger studies are needed to prove the clinical 
utility of these reagents. 
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The overall objective of this thesis was to develop immunological reagents 
against biomarkers associated with malignant transformation of cervical 
epithelium for improved diagnosis of cervical cancer.  
The specific aims were to 
 Generate useful monoclonal antibodies against HPV E7 
oncoproteins. The antibodies should have high affinity to oncogenic 
HPV types without cross-reactivity to cellular proteins. 
 Develop sensitive protocols for Immunocytochemistry, 
Immunohistochemistry and other immunoassays to assist in early 
detection of cervical cancer. 
 Evaluate the diagnostic potential of the established methods using 
representative clinical specimens. 
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Three cervical cancer cell lines were obtained from the American Type 
Culture Collection (ATCC) and used as positive and negative controls 
throughout the studies; CaSki (ATCC: CRL-1550) expressing the HPV16 E7 
protein, HeLa (ATCC: CCL-2) expressing the HPV18 E7 protein and C-33A 
(ATCC: HTB-31) negative for HPV DNA. The cell lines have the major 
advantage of being monoclonal, compared to the mixed nature of patient 
samples and are therefore trustable controls. 
 
Two different immunization strategies were employed in this study; Site-
specific immunization with peptides displayed on phage particles and 
immunization with full-length recombinant HPV E7 protein. Female Balb/c 
mice (B&K Universal) were used and kept at the Experimental Biomedicine 
facility, Sahlgrenska Academy at the University of Gothenburg. All 
experiments were approved by the Ethical Committee for Animal 
experimentation in Gothenburg, Sweden. 
The mice were intraperitoneally injected with either 5 x 1011 phage particles 
displaying E7 peptides, or first 25 μg and then 10 μg recombinant HPV16 or 
18 E7 protein, in Sigma Adjuvant System. The serum reactivity against the 
full-length E7 protein was studied by ELISA and spleen cells from high-titer 
mice were collected for the establishment of antibody-producing hybridomas. 
Newly isolated B-lymphocytes were fused with the mouse myeloma cell line 
P3X63Ag8.653 (ATCC: CRL-1580), by treating the cells with Polyethylene 
glycol (PEG) in a strictly controlled manner65. The newly fused cells were 
grown in 96-well plates and selected through the addition of hypoxanthine, 
aminopterin and thymine (HAT) to the growth media (Fig. 8). The resulting 
hybridomas were then selected for reactivity to full-length HPV16 or 18 E7 
in ELISA. 
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Figure 8. Fusion and in vitro selection of in HAT medium. When aminopterin (A) is 
added to the growth media normal DNA synthesis is inhibited and the cell has to use 
a salvage pathway (PW) which requires hypoxanthine (H) and thymine (T) for DNA 
synthesis. The mutant mouse myeloma cell line (M) is defective in one of the genes 
necessary for the salvage pathway and will die in the presence of aminopterin. 
Myeloma cells fused with B-cells (B), however, are provided with the necessary 
genes and become immortal antibody-producing hybridomas. Non-fused  
B-lymphocytes only survive for up to two weeks in culture. Ig: Immunoglobulin.  
Different immunological methods, primary ELISA, but also Western blot and 
Immunocytochemistry, were used to identify antibodies with the desired 
properties. Antibodies with reactivity to the low-risk HPV types were 
discarded and the high-risk specific ones were further evaluated. Promising 
hybridomas were expanded and cloned by limiting dilution. Antibody (Ab) 
isotypes were determined by ELISA using isotype-specific antibodies. 
The mAbs used in all studies, were produced by in vitro cultivation in 
Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich) with 2.5 % 
FBS and 1 % DMEM supplement in roller bottles. The antibodies were 
purified on Protein A and eluted at pH 4. Purity and concentration were 
determined by gel chromatography and by measuring the absorbance at 
280 nm. 
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Phage display, display of peptides on the surface of the bacteriophage, has 
become a widely used technique to study protein interactions and produce 
large amounts of peptides attached to the phage carrier. Wild-type 
filamentous phage particles are rod-shaped and composed of a single-
stranded phage genome, covered by approximately 2700 copies of the major 
pVIII protein and five copies each of the minor coat proteins pIII and pVI. By 
cloning a chosen nucleotide sequence in fusion with one of the phage coat 
proteins, either directly into a modified phage genome or into a separate 
phagemid, phage particles displaying the corresponding peptide on its surface 
are created66. Phagemids are plasmids carrying a modified gene of one of the 
phage coat proteins together with antibiotic resistance and both a plasmid and 
a phage replication origin. A wild-type so called helper phage is then needed 
to support phage production. The resulting phage preparation is be a mixture 
of phage particles, carrying either the helper phage genome or the phagemid, 
all displaying the peptide encoded by the phagemid on a portion of its coat 
proteins. In this study, phage display was used for the construction of 
overlapping E7 peptide libraries for epitope determination, immunization of 
mice and mimotope mapping with commercial random peptide libraries. 
 
Phage particles are immunogenic and can thus be used as immunogenic 
carriers of peptides67. In paper I, phage display was used for Site-specific 
immunization, to direct the immune system to a specific pre-defined region 
of the E7 protein. A high-risk specific region of the HPV16 E7 sequence, 
corresponding to aa 33-60 of the E7 protein, was identified and cloned in 
phage vector f88-4, kindly provided by professor G.P. Smith (University of 
Missouri, Columbia, US), in fusion with the major coat protein pVIII. Phage 
particles were produced in E. coli, purified by double PEG precipitation and 
used to immunize mice. Spleen cells from mice with high HPV16 E7 titer 
were used to establish antibody-producing hybridomas, as described above. 
Serum reactivity as well as the reactivity of the resulting antibodies was 
measured by ELISA against full-length E7 protein. 
 
Since phage particles carry the sequence encoding the peptide it displays it is 
suitable for the construction of peptide libraries. Phage clones binding to a 
specific target, such as a mAb can be selected from the library in a panning 
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process. The sequences of the identified phage clones reveal the region, 
epitope or mimotope involved in binding. 
In paper I and II, overlapping HPV E7 peptides, 16 to 37 aa long, were 
displayed on phage and antibody binding to the different clones was studied 
by ELISA. The antibodies to be examined were immobilized in microtiter 
wells and different phage clones were added each wells. After washing off 
the non-binding phage particles, phage binding was detected by incubation 
with a rabbit-anti-M13 antibody (raised against M13 phage particles at 
Fujirebio Diagnostics AB), a Horseradish peroxidase (HRP)-conjugated 
swine-anti-rabbit Immunoglobulin (Ig, Dako) and the HRP substrate Enhance 
K-blue (Neogen). The binding pattern to the different phage clones thereby 
directly revealed the E7 regions involved in binding. 
 
In paper I and III, a commercially available random 7-mer peptide library 
displayed on phage (New England Biolabs) was used for mimotope 
identification. The library was panned against the mAbs in four rounds and 
binding clones were identified and sequenced. The consensus aa sequences 
were compared with the E7 aa sequence and aa essential for binding, the 
mimotope, were identified. 
 
In paper III, three vectors for the display of peptides on either bacteriophage, 
in fusion with Glutathione-S-Transferase (GST), or in fusion with the cholera 
toxin B subunit (CTB) were generated. The vectors and inserts were designed 
so that the synthesized DNA could be cloned into any of the three vectors, 
depending on application. By arranging the peptide-encoding fragments, 
interspersed with linkers carrying restrictions sites for cloning, on the same 
DNA construct cloning of the entire library could easily be performed in a 
single reaction mix (Fig. 9). Here, the vector system was used to create 
libraries of HPV16 E7 peptides, 12 aa long, covering the entire E7 open 
reading-frame (ORF) and overlapping by 8 aa. 
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Figure 9. Arrangement of overlapping sequences for cloning into expression vectors. 
Alternating inserts were inverted to minimize the number of bases to synthesize and 
shuffled to reduce secondary structure of overlapping sequences. The restriction sites 
(represented by X and Y) on the inserts and expression vectors were placed so that 
the vectors could be used interchangeably. The digested inserts were 
dephosphorylated to prevent them from ligating to each other. 
Four HPV16 E7 mAbs were epitope mapped by colony blot, using the E7 
peptide library fused to GST. 135 random clones from the library were grown 
as single colonies in a grid pattern on LB plates and then transferred to sterile 
nitrocellulose filters by placing them on top of the colonies. The filters were 
then placed on fresh LB agar plates supplemented by IPTG to induce the 
expression of the GST fusions. The cells on the filters were lysed and the 
filters were incubated with the HPV16 E7 mAbs. MAb-binding was detected 
using HRP-conjugated goat anti-mouse Ig and visualized with HRP substrate 
2-chloronaphtol. Plasmids of the positive clones on the filter were prepared 
from the same position on the corresponding LB-plate and sequenced.  
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The same overlapping HPV16 E7 peptides, displayed on phage particles, 
were used to map dominant B-cell epitopes in crude serum from mice 
immunized with full-length HPV16 E7 protein. The serum to be mapped was 
immobilized in microtiter wells. A mixture of 108 phage particles, 
corresponding to nearly 5 x 107 copies of each phage clone, was added to 
each well and 20 binding clones were sequenced after one round of panning. 
The peptide sequences were compared to the HPV16 E7 sequence to identify 
linear B-cell epitopes. 
 
ELISA (Enzyme-linked immunosorbent assay) offers the opportunity to 
study antibody interaction to the native antigen in solution. In this study, 
ELISA was used for different applications such as specificity studies with 
recombinant antigen, epitope mapping with phage particles and to monitor 
immune response in immunized mice. Although variables such as incubation 
times and Ab concentrations varied between applications, the key steps are 
common to all. 
The catching antibody was immobilized in Maxisorp wells (Nunc A/S), 
either directly or, for unpurified Ab caught by an immobilized polyclonal 
goat-anti-mouse Ig antibody (Jackson Immunoresearch Laboratories). After a 
wash step, the antigen, diluted in blocking buffer was added. Antigen binding 
was detected using antibodies directed directly against the E7 protein or 
against a protein tag such as the phage particle or GST and an HRP-
conjugated secondary antibody. Two different HRP substrates were used, 
either the o-Phenylenediamine (OPD) substrate (Sigma-Aldrich) or the more 
sensitive Enhance K-Blue (Neogen) substrate. Absorbance was measured at 
450 or 620 nm in a microplate spectrophotometer (Vmax, Molecular 
Corporation), depending on the substrate used. An automatic plate washer, in 
strip mode with overflow, with 5mM Tris-HCl pH 7.8, 150 mM NaCl and 
0.005 % Tween20. All incubations were at room temperature, either in a 
humid chamber or on a microplate shaker (900-1100 oscillations/min). When 
measuring serum reactivity against the E7 protein, GST-tagged E7 protein 
was directly coated in glutathione-coated wells (Pierce). Serial dilutions of 
serum were added to the E7-coated wells and anti-E7 reactivity was detected 
with HRP-conjugated rabbit anti-mouse (Dako). 
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The specificity of antibodies was also studied by Western blot. A panel of 
high- and low-risk (HPV1, 6, 11, 16, 18, 31, 33, 35 and 45) E7 proteins were 
separated by SDS-PAGE (NuPAGE) and blotted to PVDF membranes. The 
membranes were incubated with the E7 antibodies in 5 % non-fat dry milk 
and binding was detected with HRP-conjugated rabbit anti-mouse Ig (Dako) 
and chemiluminescent detection (ECL+, GE Healthcare). 
Western blot was also used to ensure that the antibodies did not cross-react 
with other proteins present in cervical cells. Cell lysates were prepared from 
cervical cancer cell lines CaSki (expressing HPV16 E7 protein), HeLa 
(expressing HPV18 E7 protein) and C-33A (negative for HPV DNA). The 
cells were lysed by freeze-thawing and cell debris was removed by 
centrifugation. The total protein concentration was determined with the Bio-
Rad protein assay kit and 50 μg of protein was loaded to each lane. The 
analysis was then done as described above. 
 
All high-risk HPV-specific antibodies were evaluated using Immuno-
cytochemistry (ICC). The newly harvested cervical cancer cell lines were 
either directly mounted on polysine slides and fixed in 10 % neutral buffered 
formalin or first fixed in the LBC preservative fluid (Thinprep Preservcyt, 
Hologic or Surepath, BD) and then mounted on slides. Different methods and 
buffers for antigen retrieval were evaluated such as heat-induced antigen 
retrieval in citrate or Tris buffer, to try to find the optimal protocol for each 
antibody. Other parameters, such as antibody concentrations, incubation 
times and incubation temperatures were also optimized in parallel.  
 
The optimized protocols with the anti-HPV E7 mAbs E716-41 and E718-79 
were, as presented in paper IV, evaluated on 49 patient cytology samples 
collected in Thinprep LBC fluid (Hologic). All samples were HPV DNA 
genotyped. 19 samples were judged as normal in the cytological evaluation. 
The 20 dysplastic samples, all HPV16 or 18 positive, were from a referral 
population and cytology samples and biopsies for histological evaluation 
were taken at the same visit. All women provided informed consent. 
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The samples were either mRNA genotyped or evaluated in p16/Ki-67 
cytology (CINtech PLUS, mtm laboratories AG). All mRNA genotype 
results were in agreement with the DNA genotyping. For p16/Ki-67 
evaluation only double stained cells, with red nucleus and brown cytoplasm, 
were considered as positive. E7 cytology was interpreted as positive if cells 
abnormal cells were stained. All slides were evaluated by trained cytologists. 
The cytologists knew the distribution of the specimens, but were blinded to 
the specific cytology diagnosis and HPV genotype result. The E7 cytology 
results were then correlated to HPV mRNA status, p16/Ki-67 cytology and 
histology results. 
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Using two different immunization strategies, over 100 hybridomas producing 
anti-HPV16 or HPV18 E7 antibodies were established. From these, high-risk 
HPV-specific antibodies with different properties were selected, with focus 
on finding those that detected the antigen by ICC, especially in LBC samples. 
The identified antibodies had different specificities and properties depending 
on the immunogen and selection method used. (Fig. 10) 
Figure 10. Schematic presentation of the workflow. Two different immunization 
strategies were used; Site-specific immunization with a high-risk specific HPV16 E7 
peptide displayed on phage particles and immunization of recombinant full length E7 
protein. Spleen cells from mice with high serum titers against full-length recombinant 
E7 were fused with a mouse myeloma cell line to get antibody-producing immortal 
hybridomas. The primary screening of the hybridomas was done by ELISA against 
full-length HPV16 and 18 E7 proteins. The reactivity of the selected hybridomas 
were further evaluated against a panel of high- and low risk HPV types in ELISA and 
Western blot and the epitopes were roughly mapped using overlapping E7 peptides 
displayed on phage. High-risk HPV-specific antibodies (Ab) were cloned and 
carefully evaluated against endogenous E7 in Immunocytochemistry (ICC) and 
Western blot. Mimotope analysis was performed for a subset of the high-risk Abs. 
The HPV E7 protein is an antigen with more and less conserved regions. 
Antibodies, especially those reacting with the highly conserved regions, will 
most probably detect the E7 protein of several HPV types. Whether type-
specific antibodies or antibodies with broader specificity is preferred, will 
depend on the clinical application. Throughout these studies, high-risk HPV-
specific antibodies were saved while the ones cross-reacting with the 
common, but not carcinogenic HPV-types were discarded. The reason for this 
was to avoid antibodies giving false positive results. This was done by 
immunizing with high-risk specific regions of the protein (site-specific 
immunization) and by selecting for high-risk specificity. 
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Figure 11. Phylogenetic tree based on the E7 amino acid sequences of 12 high-risk 
HPV types, two low-risk HPV and the probably carcinogenic HPV type 68. Due to 
the high sequence similarity between types, E7 antibodies often detect several E7 
proteins, especially the more closely related such as HPV16, 31 and 35 or HPV18 
and 45. The types in bold are the eight most common types, together found in 
approximately 90 % of all cervical cancers. The sequence differences between high- 
and low-risk HPV E7 made the establishment of high-risk specific E7 antibodies 
possible. The phylogenetic analysis is based on the multiple alignments of the E7 
amino acid sequences in Clustal W. The evolutionary analyses were conducted in 
MEGA5. 
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Phage display is an effective method to produce large amounts of peptides 
attached to an immunogenic carrier. Phage particles displaying pathogen-
derived peptides induce protective immunity to that specific pathogen68, 69 
and phage clones displaying mimotopes mimicking specific antibody 
epitopes and selected from random libraries, can activate immune responses 
against the original antigen70, 71. Site-specific immunization with phage 
particles is an attractive approach when antibodies to a specific part of a 
protein are wanted for example in sandwich pairing, or to avoid highly 
immunogenic regions. Further, as phage particles are immunogenic and 
persist in the circulation or longer than free peptides that are rapidly cleared, 
site-specific immunization is a preferable alternative when antibodies to less 
immunogenic regions are needed. 
In paper I, the immunogenicity of the phage particles was used to direct the 
immune response to a specific region of the HPV16 E7 oncoprotein thereby 
raising antibodies recognizing a pre-defined region of the endogenous E7 
protein. A high-risk specific region, aa 33-60 of the HPV16 E7 protein was 
identified by sequence analysis. This fragment of HPV16 E7 has large 
sequence homology to the E7 protein of the closely related HPV types 31, 33 
and 35, but not to the low-risk types or less related high-risk types, such as 
HPV18. The region was further chosen not to include the conserved regions, 
CR1-3. The corresponding nucleotide sequence was cloned into phage 
display vector f88-4, resulting mosaic phage particles with approximately 
5 % of the pVIII proteins fused with the E7 peptide. 
After seven immunizations with the phage preparations during the period of 
ten month, two out of three mice had high serum reactivity towards full-
length HPV16 E7 and were sacrificed for hybridoma production. The fusion 
procedure resulted in three hybridomas, with reactivity to the HPV16 E7 
protein, which were cloned by limiting dilution and evaluated using different 
immunological methods, in both paper I and II. 
The three antibodies, named E716-1, E716-2 and E716-9 recognized full-
length recombinant E7 of the three closely related high-risk types HPV16, 31 
and 35, but not HPV 1, 6, 11, 18, 33 or 45, in ELISA and Western blot. The 
reactivity to the denatured protein in Western blot indicated that the 
antibodies recognize linear epitopes. The antibodies further detected the 
endogenous HPV16 E7 protein in lysates of the HPV16-positive cervical 
cancer cell line CaSki in Western blot, without cross-reactivity to other 
cellular proteins present in the lysates or to HPV18 E7 in HPV18-positive 
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HeLa cells. The mAbs specifically stained the HPV16 E7 protein in formalin 
fixed CaSki cells in ICC, indicating that the antibodies can be used to detect 
HPV16-induced malignancy in formalin fixed clinical samples.  
Since the mice were immunized with an HPV16 E7 peptide corresponding to 
aa 33-60 of the HPV16 E7 fragment, the resulting antibodies recognized this 
region. To further characterize the epitopes fragment phage display was used. 
Three peptides together covering the peptide used for immunization were 
displayed on phage particles. The reactivity of the antibodies to the different 
fragments was studied in ELISA and from the binding pattern, the epitope 
was narrowed down further. E716-1 and E716-9 recognized the two 
fragments aa 28-47 and 37-53, mapping the epitope to the overlapping region 
aa 37-47. Antibody E716-2 only bound one fragment aa 37-53, mapping the 
epitope of E716-2 to the junction between the other two fragments (aa 28-47 
and 47-62) (Fig. 12). 
To further confirm the mapping data and support the specificity results, 
mimope analysis was done with a commercially available random peptide 
library displayed on phage. The peptides of the library used here was only 
7 aa long and therefore ideal for mapping of linear B-cell epitopes, though 
conformation dependent epitopes cannot be identified with such short 
peptides. The phage library, displaying the random peptides in fusion with 
the pIII coat protein, was panned against the antibodies in four rounds. Nine 
binding clones were sequenced for each mAb and the consensus sequence 
revealed the aa residues necessary for antigen binding, the mimotope. E716-1 
and E716-9 had the exact same mimotope, Q A/S Q/R PD, corresponding to 
aa 44-48 on the HPV16 E7 sequence. This sequence is conserved between the 
three closely related types HPV16, 31 and 35 in agreement with the 
specificity study with recombinant protein and cannot be found in the other 
HPV E7 proteins. The mimotope of E716-2 was one position longer, 
Q A/S R PDR, corresponding to aa 44-49. This sequence can only be found in 
HPV16 E7, but since E716-2 also detects HPV31 and 35, the last position of 
the mimotope, the Arginine (-R-) is not crucial for binding. Altogether, the 
study shows how different methods can be used to complement and confirm 
results in the establishment of highly specific and well characterized 
antibodies for clinical applications. 
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Figure 12. Mapping results for the three HPV16 E7 antibodies raised by site-
specific immunization. The antibodies were raised against amino acid (aa) 33-60 
of the HPV16 E7 protein (underlined sequence). This region was chosen due to 
the sequence homology with a group of high-risk viruses (e.g. 31 and 35). The 
resulting antibodies detected mimotopes corresponding to aa 44-48 and 44-49 
and recognize recombinant HPV16, 31 and 35 E7 but not HPV18 E7 or low-risk 
HPV6 or 11 E7 protein. 
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A more widely used strategy for the establishment of monoclonal antibodies 
is to immunize the animals with full-length protein. In paper II, recombinant 
HPV16 and 18 E7 was used for immunization. The primary hybridoma 
selection was against recombinant HPV16 or 18 E7 proteins in ELISA and 
only hybridomas detecting either of the proteins were saved. This resulted in 
57 hybridomas. The specificity was further evaluated in ELISA against a 
panel of high- and low-risk E7 proteins and those that cross-reacted with low-
risk types were not further evaluated, resulting in 35 high-risk HPV-specific 
hybridomas. The majority of the antibodies recognized the E7 protein from 
more than one HPV type, which is not at all surprising, given the large 
sequence similarity throughout the viral genome. Most of the high-risk 
specific antibodies recognized a few, closely related HPV types, such as 
HPV18 and 45 or HPV16, 31 and 35. 
The same panel of recombinant E7 proteins was used to study antibody 
specificity in Western blot. All the anti-E7 antibodies, selected for high-risk 
specificity against recombinant E7 in ELISA and functionality in ICC, had 
linear epitopes and recognized the E7 protein using Western blot. Overall, the 
specificity results from the Western blot analysis agreed with the ELISA 
analysis. The minor discrepancy seen between the two techniques is probably 
due to differences in affinities and how the specific epitopes are exposed. 
As in paper I, overlapping peptides displayed on phage particles were used 
for epitope determination (Fig. 13). However, since the antibodies in paper II 
were raised against full-length protein fragments covering the entire HPV16 
and HPV18 E7 ORFs were used. The peptides were of different length, from 
16 to 37 aa long and displayed on phage particles in fusion with either coat 
protein pVIII or pIII. Antibody binding to the different peptides was then 
studied in ELISA to map the antibody epitopes. Epitope mapping with long 
peptides is a fast and straightforward technique to roughly identify the 
epitopes of a large number of antibodies targeting the same antigen. A 
separate set of clones has to be constructed for each antigen, but when this 
has been done, a large number of antibodies can easily be mapped in parallel. 
The mapping data can be used to for example find possible ELISA pairs, 
predict antibody specificities or identify immunogenic regions on an antigen. 
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Figure 13. Epitope mapping of 57 antibodies (Ab) raised against the full-length 
HPV16 or 18 E7 protein. In total, 48 hybridomas recognized to the first 22 amino 
acids of the E7 protein, a region that includes conserved region (CR) 1 and several 
well conserved positions. The majority of these N-terminal antibodies recognized 
several HPV-types and only 14 were HPV16 or 18-specific. All antibodies that 
detected more central part of the protein were high-risk specific. 
As expected, the 57 hybridomas targeted different regions of the E7 antigens. 
However, the majority of the antibodies were directed to the N-terminal of 
the E7 protein and all 57 antibodies actually detected epitopes within aa 1-53, 
a region which is known to lack secondary structure35. This is in agreement 
with earlier studies identifying the N-terminal half of the E7 protein as more 
immunogenic72. All 22 hybridomas that cross-reacted with the low-risk HPV 
types, detected aa 1 to 22, including CR1 which is highly conserved 
throughout all HPV E7 proteins. The majority of the N-terminal antibodies 
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did not however, detect the E7 protein in ICC, indicating that the amino 
terminus is immunogenic but not well accessible in ICC.  
In our hands, site-specific immunization gave fewer positive hybridomas than 
immunization with full-length protein, but since all detected the desired 
region the selection process was short and no hybridomas were discarded due 
to cross-reactivity to low-risk types. When immunizing with full-length 
protein the more immunogenic regions of the protein obviously dominated 
but after a more laborious selection process involving a much larger number 
of hybridomas high-quality antibodies with different specificities and 
functionalities were identified. When antibodies to a protein like E7 with 
highly immunogenic, conserved regions are wanted site-specific 
immunization might be a more efficient option to obtain antibodies with the 
desired specificity. 
 
A vector system for the display of peptide libraries on phage particles or in 
fusion with GST or CTB was constructed. The inserts encoding the peptides 
to be displayed were arranged on long synthesized DNA constructs, with 
restriction sites in between, so that they could be inserted in any of the three 
expression vectors, depending on application. Using the described method, a 
12-mer library, overlapping by 8 aa and covering the entire ORF of HPV16 
E7 was constructed. The library was used to identify HPV16 E7 antibody 
epitopes and map antibody reactivity in HPV16 E7 immunized mice. 
Four HPV16 E7 antibodies where examined with colony blotting, using the 
12-mer library displayed in fusion with GST and the epitopes were mapped 
down to four to twelve amino acids. The mapping results were in agreement 
with earlier results using longer overlapping peptides and the random 7-mer 
peptide library (Table 1). The mimotope of two mAbs, E716-9 and E716-41 
had previously been mapped with the random peptide library. The mimotope 
of E716-9 was identified as Q A/S Q/R PD and two 12-mer peptides in the 
overlapping library carry this epitope. However, only one was isolated 
indicating that there are some conformational constrains or that all clones 
were not represented among the 135 colonies in the blot. The epitope of 
E716-41 was mapped down to four amino acids, HEYM, corresponding to 
aa 9-12 on the HPV16 E7 sequence and in agreement with mimotope data 
identifying HE Y/F as necessary for binding. 
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Table 1. Epitope identification of three HPV16 E7 mAbs using three 
complementary techniques. 
The 12-mer E7 library was also displayed on phage particles and used to map 
antibody responses in serum of mice immunized with full-length recombinant 
HPV16 E7 oncoprotein. After a single round of panning the library against 
serum immobilized in microtiter wells, 2.8 x 104 particles were eluted 
compared to 400 from naïve serum. 20 of these were sequenced which was 
enough to obtain conclusive results. The panning experiment showed that the 
serum reactivity in the E7 immunized mice was predominately directed to the 
N-terminal of the HPV16 E7 protein, while that of the control animals was 
randomly distributed. This further proved the immunogenicity of the amino 
terminus seen when hybridomas were raised against full-length E7 protein in 
paper II. The constructed library can thus be used to map dominant B-cell 
epitopes and predict the antibody specificities of the resulting hybridomas. In 
antibody production, this can be used to choose mice with the desired 
antibody response for hybridoma production and encourage the use of 
alternative immunization strategies to obtain antibodies to less immunogenic 
regions such as site-specific immunization. Mapping of B-cell epitopes to 
different antigens is also important for other applications, such as the analysis 
of immune response to vaccines or pathogens. 
Overlapping peptide libraries are obviously an easy way of mapping several 
antibody epitopes to the same antigen and can even be used to map 
conformational dependent epitopes. Several studies have shown that peptides 
often better mimic antibody epitopes when attached to the hydrophobic phage 
Clone Method Consensus sequence 
Corresponding aa of the 
HPV 16 E7 protein 
    
E716-9 E7 peptide display EIDGPAGQAEPD 37-47 
 12-mer peptides EIDGPAGQAEPD 37-48 
 Mimotope        QxxPD 44-48 
    
E716-41 E7 peptide display MHGDTPTLHEYM 1-12 
 12-mer peptides         HEYM 9-12 
 Mimotope         HEY 9-11 
    
E716-74 E7 peptide display  EPDRAHYN 46-53 
 12-mer peptides     RAHYNIVT 49-56 
    
E716-81 E7 peptide display MHGDTPTLHEYM 1-12 
 12-mer peptides     TPTLHEYM 5-12 
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surface as compared to free peptides70, 73, 74. Peptide libraries can in addition 
be used to map antibody epitopes to a specific target in a mixture of other, 
irrelevant antibodies or antibodies with several specificities to the same 
antigen, such as crude serum and polyclonal antibodies. A new library has to 
be constructed for each antigen, but once this is done, is a continuous, 
inexpensive source of peptides, compared to e.g. Pepscan. Random peptide 
libraries can only be used on antibodies with single specificities, but can on 
the other hand be used to map antibodies with unknown specificities. The 
mimotope data from random libraries can be used to search sequence 
databases, thereby identifying possible interaction partners for a specific 
antibody. 
 
 
All high-risk specific antibodies raised in this study were carefully evaluated 
in ICC using different protocols for fixation, antigen retrieval and antibody 
staining. As presented in paper II, ten high-risk specific E7 antibodies 
detected the endogenous protein in formalin-fixed cells. Seven of the 
antibodies also stained cervical cancer cell lines fixed in LBC fluid, with an 
overall higher sensitivity than in formalin fixed cells. A difference in staining 
between the two fixatives is expected since formalin is a crosslinking fixative 
while the alcohol of the LBC fluid denatures the proteins. As the epitopes are 
often differently exposed in different fixatives75, ICC protocols have to be 
evaluated for every specific antibody/antigen pair and fixative. As seen both 
in this and other studies ICC staining could not be achieved with all 
antibodies established which is probably due to both epitope conformation 
and antibody properties such as affinity.  
Heat-induced antigen retrieval had no positive effect on staining in any of the 
protocols with any of the antibodies, but incubation with Triton X-100 
improved staining of LBC samples considerably and is included in the final 
protocol. This positive effect of Triton X-100 on E7 staining has previously 
been reported
62
, but whether this positive effect is caused by unmasking of 
epitopes or permeabilization of cell membranes is not known. 
The optimized protocol was the same for all antibodies and the only 
parameter that differed between the protocols was antibody concentration. 
After mounting and fixation in either formalin or LBC preservative, the cells 
were pretreated for 15 minutes with 0.3 % Triton X-100 followed by 
blocking of endogenous peroxidases for 5 min in 1 % hydrogen peroxide. 
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The slides were then incubated with the E7 antibodies, diluted to the optimal 
concentration in Dako antibody diluent, in a humid chamber. E7 antibody 
binding was visualized with REAL EnVision Detection system (Dako) and 
diaminobenzidine (DAB), staining the E7-expressing cells brown. To 
facilitate identification of cell morphology, the cells were counterstained blue 
with haematoxylin. 
The final ICC protocols for detection of E7 in LBC were highly sensitive and 
able to detect single HPV positive cells in a background of HPV negative 
cells (Fig. 14). The most promising antibodies were mAb E716-41, specific 
for HPV16 E7 and E718-79, specific for HPV18 E7. If constructing a test 
based on these two HPV types it would cover approximately 70 % of all 
cervical cancers6. The cells were stored in the LBC liquid for over two years 
without loss of signal or adding background. This indicates that the 
antibodies have the potential to be used in a clinical setting to detect and 
highlight rare dysplastic cells in LBC samples. 
Figure 14. To mimic a clinical sample with only a proportion HPV-positive cells 
in a background of uninfected cells, HPV16-positive CaSki cells and HPV18-
positive HeLa cells were mixed, in different proportions, with the HPV negative 
cervical cancer cell line C-33A and stained with a) mAb E716-41 and b) mAb 
E718-79. Both antibodies easily detected 1 % of HPV-positive cells without 
staining C-33A76. 
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Only a few studies have been able to detect the E7 protein in cervical 
cytology samples
62, 77
 and to our knowledge no studies have shown E7 ICC 
staining of clinical LBC samples. In paper IV, the most promising ICC mAbs 
E716-41 and E718-79, were evaluated on 49 clinical samples stored in LBC 
fluid. Histology, HPV DNA genotyping, HPV mRNA genotyping and 
p16/Ki-67 staining was performed in parallel. Both antibodies were able to 
detect the E7 protein in dysplastic HPV-infected samples without staining 
normal cytology samples and can potentially be included in a test to detect 
the HPV16 and 18 E7 proteins in residual LBC samples. 
Figure 15. Evaluation of the E7 cytology protocols on clinical LBC samples. 
Staining of an HPV16 positive histologically verified cervical intraepithelial 
neoplasia (CIN) 2 sample with a) mAb E716-41 and b) p16/Ki-67 dual staining. 
The E7 protocols stain both nucleus and cytoplasm of dysplastic cells brown.  
The haematoxylin stains all cells blue.  
The p16/Ki-67 staining was used to identify dysplastic cells in the LBC 
samples. Getting an estimation of the number of dysplastic cells actually 
present in the sample facilitated the evaluation of the E7 staining. In all 
samples, the number of E7-positive cells was the same or fewer than those 
detected by the p16/Ki-67 staining. This difference is most likely due to 
lower levels of E7 protein expressed in the cells compared with the 
accumulated secondary markers and not the sensitivity of E7 antibodies since 
both have affinity constants in the order of 10-10 (determined by QCM, 
unpublished data). False positive p16/Ki-67 staining is also a possible 
explanation since the secondary markers can be elevated for other reasons 
than in response to HPV-infection78. For five samples, histologically verified 
as high-grade lesions (CIN2-3), no cells were stained with p16/Ki-67, 
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indicating that no dysplastic cells were actually present in the cytology 
sample. The same samples were also negative for E7 staining. Deviation 
between cytology and histology results is normal, due to both sampling 
techniques and biological variations, though it can be minimized through 
training and method optimization. ICC protocols, such as those presented 
here, can however highlight the dysplastic HPV-positive cells present in the 
scrape, possibly irrespectively of morphology, thereby increasing specificity 
and sensitivity and reduce inter-observer variability. 
The antibodies evaluated in paper IV, clearly stain dysplastic cells of 
different severity (Fig. 15). New complementary tests for borderline and 
ASC-US cytology are highly needed and the antibodies presented here might 
have the potential to be included in such tests. To prove clinical utility, 
however, larger studies are obviously necessary, preferably on a true referral 
population including multiple infections. Since LBC leaves residual sample 
after the cytology evaluation the E7 staining can be done on the same sample, 
without recalling the patient. The protocols presented here can easily be 
accomplished in a few hours with only basic laboratory equipment and such 
tests might therefore be a cheap alternative to HPV DNA/mRNA testing or 
genotyping, or be included in an automated test to identify true cervical 
malignancy. 
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Today’s cervical cancer screening programs yearly produce millions of 
suspicious samples that require expensive retesting, recalling and follow-up. 
Only a small proportion of these women however, have underlying disease 
that needs to be detected and treated. This group should optimally be 
identified without causing too much anxiety and overtreatment in the large 
group of women who are not at increased risk of getting cervical cancer. To 
do this, complementary tests specific for high-grade dysplasia are needed. 
The antibodies presented here detect the E7 oncoprotein using different 
immunological techniques such as Western blot, Immunocytochemistry and 
flow cytometry and can also be combined in pairs for ELISA analysis. 
Immunological methods can offer objective and possibly more specific 
evaluation of HPV-induced disease as compared to cytology since elevated 
levels of E7 protein is a direct marker of malignant transformation. 
A major focus of this study has been to generate and characterize HPV E7 
antibodies in detail, regarding both specificity and usefulness in 
immunological detection of HPV-induced cancer. Well characterized 
antibodies are necessary for the construction of safe immunological tests and 
techniques for antibody establishment and characterization are obviously 
important tools in the creation of new immune reagents. The different 
immunization strategies, as well as the methods used for screening and 
epitope characterization, resulted in antibodies with different properties and 
specificities, highlighting the importance of choosing the most efficient 
strategy when generating new antibodies for a specific application. 
The generated antibodies specifically detect the E7 protein from cervical 
cancer cell lines in Western blot and ELISA. However, in these techniques 
the sample is lysed prior to analysis and the E7 protein will be diluted in the 
lysate of an unknown number of normal cells present in the cell scrape. This 
makes E7 quantification problematic and future studies will need to assess 
whether the required sensitivity for detection of E7 in clinical samples can be 
achieved using ELISA or Western blot techniques. 
Several of the antibodies presented here recognize the E7 protein in cervical 
cancer cells. A cytology sample normally contains between 500 000 and 
2 000 000 cells out of which only a few, possibly less than 0.1 %, are 
dysplastic and express E7 oncoprotein. For obvious reasons, cytology 
evaluation can be tiresome and the often small numbers of abnormal cells 
present can be hard to identify, causing large variation in diagnosis even 
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between experienced cytologists40. The antibodies described in the present 
study stain single HPV-positive cells in immunocytochemistry and 
preliminary data indicate that the antibodies can identify down to 0.1 % 
HPV-positive cells in a mixture of normal cells in flow cytometry. Both ICC 
and flow cytometry are excellent techniques to highlight rare dysplastic cells 
and offer the possibility to automatize the screening process.  
The two most promising antibodies for detection of E7 in LBC detect the two 
most common types, HPV16 and 18, together responsible for approximately 
70 % of all cervical cancers6. The remaining types in the world-wide 
distribution contribute much less to the total cancer burden and antibodies 
detecting the nine most common types would be needed to achieve 90 % 
coverage79. E7 detection can either be done with the antibodies mixed in a 
high-risk specific antibody cocktail, or as separate, type-specific staining 
protocols. Type-specific E7 cytology can be useful to identify what HPV 
type/types causes lesions in for example a patient with multiple infections. 
This could be used to determine disease prognosis and identify patients at a 
higher risk since for example HPV16 and 18 are overrepresented in more 
aggressive disease6. A mixture of antibodies, possibly both to the E6 and E7 
proteins or in combination with antibodies to other cellular markers, could be 
used to improve sensitivity further. 
Some of the major questions in cervical cancer testing are; how to reduce 
overtreatment in screened populations, how to increase sensitivity for 
malignancy detection and how to make screening available for a larger part 
of the world. No test available today can solve all these questions and new, 
simple and preferably objective tests are needed to identify women at high 
risk of proceeding to invasive disease. Immunological methods have the 
potential to offer specific and objective detection of dysplasia by detecting 
not only infection but the protein causing the malignancy and can possibly be 
included in automatized systems. Methods such as ICC or flow cytometry 
can easily be combined with HPV DNA/mRNA testing and/or cytology to 
identify rare dysplastic E7-expressing cells in a cervical sample and to 
achieve this, sensitive and specific immunological reagents are absolutely 
necessary. 
The antibodies presented here are specific for oncogenic HPV E7 protein and 
detect the target protein in tumour cells using several immunological 
methods. The most promising application is LBC and the optimized protocol 
detects single HPV16 and 18 E7 positive cells in patient material. Though 
clinical utility needs to be evaluated in larger studies, the antibodies 
hopefully have the potential to be included in a test to identify HPV-induced 
Maria Lidqvist 
38 
dysplasia in inconclusive or borderline cytology samples, thereby 
distinguishing high-grade dysplasia from transient infections and reducing 
unnecessary recalling, anxiety and overtreatment. 
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